Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide
Authors:
- Jonathan L. TsoJTJonathan L. Tso
- Shuai YangSYShuai Yang
- Jimmy C. MenjivarJMJimmy C. Menjivar
- Kazunari YamadaKYKazunari Yamada
- Yibei ZhangYZYibei Zhang
- Irene HongIHIrene Hong
- Yvonne BuiYBYvonne Bui
- Alexandra StreamASAlexandra Stream
- William H. McBrideWMWilliam H. McBride
- Linda M. LiauLLLinda M. Liau
- Stanley F. NelsonSNStanley F. Nelson
- Timothy F. CloughesyTCTimothy F. Cloughesy
Open Access
- 6 November 2015
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 14 (1) , 1-17
Abstract
Temozolomide (TMZ) is an oral DNA-alkylating agent used for treating patients with glioblastoma. However, therapeutic benefits of TMZ can be compromised by the expression of O6-methylguanine methyltransferase (MGMT) in tumor tissue. Here we used MGMT-expressing glioblastoma stem cells (GSC) lines as a model for investigating the molecular mechanism underlying TMZ resistance, while aiming to explore a new treatment strategy designed to possibly overcome resistance to the clinically relevant dose of TMZ (35 μM). MGMT-expressing GSC cultures are resistant to TMZ, and IC50 (half maximal inhibitory concentration) is estimated at around 500 μM. Clonogenic GSC surviving 500 μM TMZ (GSC-500 μM TMZ), were isolated. Molecular signatures were identified via comparative analysis of expression microarray against parental GSC (GSC-parental). The recombinant protein of top downregulated signature was used as a single agent or in combination with TMZ, for evaluating therapeutic effects of treatment of GSC. The molecular signatures characterized an activation of protective stress responses in GSC-500 μM TMZ, mainly including biotransformation/detoxification of xenobiotics, blocked endoplasmic reticulum stress-mediated apoptosis, epithelial-to-mesenchymal transition (EMT), and inhibited growth/differentiation. Bone morphogenetic protein 7 (BMP7) was identified as the top down-regulated gene in GSC-500 μM TMZ. Although augmenting BMP7 signaling in GSC by exogenous BMP7 treatment did not effectively stop GSC growth, it markedly sensitized both GSC-500 μM TMZ and GSC-parental to 35 μM TMZ treatment, leading to loss of self-renewal and migration capacity. BMP7 treatment induced senescence of GSC cultures and suppressed mRNA expression of CD133, MGMT, and ATP-binding cassette drug efflux transporters (ABCB1, ABCG2), as well as reconfigured transcriptional profiles in GSC by downregulating genes associated with EMT/migration/invasion, stemness, inflammation/immune response, and cell proliferation/tumorigenesis. BMP7 treatment significantly prolonged survival time of animals intracranially inoculated with GSC when compared to those untreated or treated with TMZ alone (p = 0.0017), whereas combination of two agents further extended animal survival compared to BMP7 alone (p = 0.0489). These data support the view that reduced endogenous BMP7 expression/signaling in GSC may contribute to maintained stemness, EMT, and chemoresistant phenotype, suggesting that BMP7 treatment may provide a novel strategy in combination with TMZ for an effective treatment of glioblastoma exhibiting unmethylated MGMT.Keywords
Funding Information
- American Cancer Society (RSG-07-109-01-CCE)
- National Cancer Institute (1 R21 CA140912-01)
- National Institutes of Health (1DP2OD006444-01)
- The Bradley Zankel Foundation
This publication has 73 references indexed in Scilit:
- BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expressionCell Death & Disease, 2012
- A restricted cell population propagates glioblastoma growth after chemotherapyNature, 2012
- Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transportersCell Death & Disease, 2011
- Interaction of Hypoxia-Inducible Factor-1α and Notch Signaling Regulates Medulloblastoma Precursor Proliferation and FateStem Cells, 2010
- Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumorsJournal of Neuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like CellsCell Stem Cell, 2009
- New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditureNature, 2008
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006